AstraZeneca Enters Licence Agreement with KYM Biosciences
Thursday, February 23, 2023
AstraZeneca and KYM Biosciences have entered into a global exclusive licence agreement for CMG901, a potential first-in-class antibody drug conjugate (ADC) targeting Claudin 18.2, a promising therapeutic target in gastric cancer.
Under the licence agreement, AstraZeneca will be responsible for the research, development, manufacture and commercialisation of CMG901 globally. In addition, this agreement with AstraZeneca consists of the potential to benefit patients in China, and throughout the world.
CMG901 is currently being evaluated in a Phase I clinical trial for the treatment of Claudin 18.2-positive solid tumours, including gastric cancer. Preliminary results from the Phase I trial showed encouraging clinical profile for CMG901, with early signs of anti-tumour activity across the dose levels tested. CMG901 strengthens the growing pipeline of antibody drug conjugates and supports to expand treatment options and transform outcomes for patients with gastrointestinal cancers.
